Opin vísindi

Development of radiographic classification criteria for hand osteoarthritis : a methodological report (Phase 2)

Skoða venjulega færslu

dc.contributor Landspitali - The National University Hospital of Iceland
dc.contributor.author Haugen, Ida K.
dc.contributor.author Felson, David
dc.contributor.author Abhishek, Abhishek
dc.contributor.author Berenbaum, Francis
dc.contributor.author Edwards, John James
dc.contributor.author Herrero Beaumont, Gabriel
dc.contributor.author Hermann-Eriksen, Merete
dc.contributor.author Hill, Catherine L.
dc.contributor.author Ishimori, Mariko
dc.contributor.author Jónsson, Helgi
dc.contributor.author Karjalainen, Teemu
dc.contributor.author Leung, Ying Ying
dc.contributor.author Maheu, Emmanuel
dc.contributor.author Mallen, Christian D.
dc.contributor.author Moe, Rikke Helene
dc.contributor.author Ramonda, Roberta
dc.contributor.author Ritschl, Valentin
dc.contributor.author Stamm, Tanja A.
dc.contributor.author Szekanecz, Zoltan
dc.contributor.author van der Giesen, Florus J.
dc.contributor.author Ritt, Marco J.P.F.
dc.contributor.author Wittoek, Ruth
dc.contributor.author Kjeken, Ingvild
dc.contributor.author Osteras, Nina
dc.contributor.author van de Stadt, Lotte A.
dc.contributor.author Englund, Martin
dc.contributor.author Dziedzic, Krysia S.
dc.contributor.author Marshall, M.
dc.contributor.author Bierma-Zeinstra, Sita
dc.contributor.author Hansen, Paul
dc.contributor.author Greibrokk, Elsie
dc.contributor.author Smeets, Wilma
dc.contributor.author Kloppenburg, Margreet
dc.date.accessioned 2022-05-11T01:03:31Z
dc.date.available 2022-05-11T01:03:31Z
dc.date.issued 2022-02-04
dc.identifier.citation Haugen , I K , Felson , D , Abhishek , A , Berenbaum , F , Edwards , J J , Herrero Beaumont , G , Hermann-Eriksen , M , Hill , C L , Ishimori , M , Jónsson , H , Karjalainen , T , Leung , Y Y , Maheu , E , Mallen , C D , Moe , R H , Ramonda , R , Ritschl , V , Stamm , T A , Szekanecz , Z , van der Giesen , F J , Ritt , M J P F , Wittoek , R , Kjeken , I , Osteras , N , van de Stadt , L A , Englund , M , Dziedzic , K S , Marshall , M , Bierma-Zeinstra , S , Hansen , P , Greibrokk , E , Smeets , W & Kloppenburg , M 2022 , ' Development of radiographic classification criteria for hand osteoarthritis : a methodological report (Phase 2) ' , RMD Open , vol. 8 , no. 1 , e002024 . https://doi.org/10.1136/rmdopen-2021-002024
dc.identifier.issn 2056-5933
dc.identifier.other 48328749
dc.identifier.other 101358e1-9f87-4319-bf43-faca703548c3
dc.identifier.other 85124173434
dc.identifier.other 35121640
dc.identifier.uri https://hdl.handle.net/20.500.11815/3159
dc.description Funding Information: Funding The project on the development of new classification criteria for hand OA is funded by EULAR. The EULAR executive committee has not been involved in the study design, analyses or interpretation of results. Funding Information: Competing interests IKH reports personal fees from Abbvie and Novartis, and research grants from Pfizer and IMI-APPROACH (both paid to the institution), all outside of the submitted work. FB reports being CEO of 4MOVING BIOTECH, received personal fees from 4P PHARMA, Boehringer, Bone Therapeutics, CellProthera, Galapagos, GSK, Lilly, Merck Sereno, MSD, Novartis, Pfizer, Servier and Peptinov, and research grant from TRB Chemedica and IMI-APPROACH (paid to the institution), all outside the submitted work. GHB reports personal fees from Pfizer, Sobi, Fresenius, Mylan, Tedec Meiji, Novartis, Sandoz and Faes, outside of the submitted work. EM reports personal fees from Expanscience, Mylan-Meda, TRB Chemedica, Pierre Fabre, Celgene and Fidia, and non-financial support from Pfizer, outside the submitted work. CDM and JJE report a research grant from BMS, outside the submitted work. RR reports personal fees from Abbvie, Celgene, Novartis, Pfizer and Lilly, outside of the submitted work. TAS reports personal fees from Sanofi, AbbVie, Roche and Takeda, outside of the submitted work. ZS reports personal fees from AbbVie, Roche, Pfizer, Berlin Chemie, UCB and Bristol-Myers, outside of the submitted work. RW reports personal fees from Abbvie, Galapagos, UCB, Bristol Myers Squib and Tilman, and grants from Amgen, outside the submitted work. ME reports serving on an advisory board for Pfizer (tanezumab) and research grant from IMI-APPROACH (paid to the institution), outside of the submitted work. SB-Z reports personal fees from Infirst healthcare, Pfizer and Osteoarthritis and Cartilage, outside the submitted work. PH is a co-inventor of the 1000minds software used in this study. MK reports personal fees from Abbvie, Pfizer, Levicept, GlaxoSmithKline, Merck-Serono, Kiniksa, Flexion, Galapagos, Jansen, CHDR, Novartis and UCB, and research grants from Pfizer, IMI-APPROACH (all paid to the institution), and royalties from Wolters Kluwer and Springer Verlag, all outside the submitted work. YYL reports grants from National Medical Research Council of Singapore, and personal fees from Abbvie, DKSH, Janssen, Novartis and Pfizer, all outside the submitted work. Publisher Copyright: © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
dc.description.abstract ObjectivesIn Phase 1 of developing new hand osteoarthritis (OA) classification criteria, features associated with hand OA were identified in a population with hand complaints. Radiographic findings could better discriminate patients with hand OA and controls than clinical examination findings. The objective of Phase 2 was to achieve consensus on the features and their weights to be included in three radiographic criteria sets of overall hand OA, interphalangeal OA and thumb base OA.MethodsMultidisciplinary, international expert panels were convened. Patient vignettes were used to identify important features consistent with hand OA. A consensus-based decision analysis approach implemented using 1000minds software was applied to identify the most important features and their relative importance influencing the likelihood of symptoms being due to hand OA. Analyses were repeated for interphalangeal and thumb base OA. The reliability and validity of the proposed criteria sets were tested.ResultsThe experts agreed that the criteria sets should be applied in a population with pain, aching or stiffness in hand joint(s) not explained by another disease or acute injury. In this setting, five additional criteria were considered important: age, morning stiffness, radiographic osteophytes, radiographic joint space narrowing and concordance between symptoms and radiographic findings. The reliability and validity were very good.ConclusionRadiographic features were considered critical when determining whether a patient had symptoms due to hand OA. The consensus-based decision analysis approach in Phase 2 complemented the data-driven results from Phase 1, which will form the basis of the final classification criteria sets.
dc.format.extent 2510866
dc.format.extent
dc.language.iso en
dc.relation.ispartofseries RMD Open; 8(1)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Slitgigt
dc.subject Hendur
dc.subject Gigtarlæknisfræði
dc.subject epidemiology
dc.subject health care
dc.subject osteoarthritis
dc.subject outcome assessment
dc.subject Radiography
dc.subject Reproducibility of Results
dc.subject Hand/diagnostic imaging
dc.subject Humans
dc.subject Osteoarthritis/diagnostic imaging
dc.subject Immunology and Allergy
dc.subject Rheumatology
dc.subject Immunology
dc.title Development of radiographic classification criteria for hand osteoarthritis : a methodological report (Phase 2)
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.doi 10.1136/rmdopen-2021-002024
dc.relation.url http://www.scopus.com/inward/record.url?scp=85124173434&partnerID=8YFLogxK
dc.contributor.department Faculty of Medicine
dc.contributor.department Internal Medicine and Emergency Services


Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:

Skoða venjulega færslu